Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E29.46 EPS (ttm)13.85 Insider Own0.10% Shs Outstand235.23M Perf Week2.99%
Market Cap95.99B Forward P/E21.00 EPS next Y19.43 Insider Trans-22.50% Shs Float235.00M Perf Month5.21%
Income3.28B PEG1.75 EPS next Q4.06 Inst Own92.30% Short Float1.10% Perf Quarter-2.40%
Sales10.13B P/S9.48 EPS this Y58.40% Inst Trans0.00% Short Ratio1.66 Perf Half Y21.18%
Book/sh49.65 P/B8.22 EPS next Y16.39% ROA23.30% Target Price476.38 Perf Year25.29%
Cash/sh9.15 P/C44.60 EPS next 5Y16.84% ROE30.90% 52W Range290.85 - 480.18 Perf YTD20.21%
Dividend- P/FCF29.63 EPS past 5Y29.90% ROI26.20% 52W High-15.02% Beta0.94
Dividend %- Quick Ratio2.30 Sales past 5Y17.30% Gross Margin88.10% 52W Low40.30% ATR8.30
Employees7550 Current Ratio2.70 Sales Q/Q20.00% Oper. Margin43.20% RSI (14)58.12 Volatility2.04% 1.96%
OptionableYes Debt/Eq0.05 EPS Q/Q72.80% Profit Margin32.40% Rel Volume0.96 Prev Close404.63
ShortableYes LT Debt/Eq0.05 EarningsJul 23 BMO Payout0.00% Avg Volume1.55M Price408.06
Recom2.20 SMA202.04% SMA503.37% SMA2009.93% Volume1,485,939 Change0.85%
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jul-07-15 01:19PM  Biogen Sees Promise in Gene Therapy at Motley Fool
Jul-06-15 08:51PM  Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015 Business Wire
03:58PM  Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News
03:05PM  Are Patent Challenges Paying Off For Kyle Bass?
09:50AM  Healthcare Stocks Likely to Outperform despite Rate Hike
07:51AM  Biogen Collaboration With Applied Genetic Is 'Interesting,' But Morgan Stanley Will Wait For More Data
07:00AM  Competition Rising for Baxalta at Morningstar
Jul-03-15 02:00PM  Applied Genetic Up on Biogen Deal for Eye Disease Drugs - Analyst Blog
12:30PM  What You May Have Missed In Biotech: Celgene's $1B Bet On Cancer Immunotherapy, And A New CF Drug at Forbes
Jul-02-15 05:05PM  Xoom Zooms, Teladoc Sinks a Day After Debut -- Tech Winners and Losers at TheStreet
03:30PM  Biogen: Where Did That Come From? at Barrons.com
03:27PM  Applied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen Deal at TheStreet
12:57PM  Why Applied Genetic Technologies Corporation Stock Jumped Today at Motley Fool
12:48PM  Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments at The Wall Street Journal
12:02PM  Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConforMIS, Health Net And More
11:28AM  Biogen, AGTC Link Up To Develop Gene Therapy at Investor's Business Daily
11:12AM  Biogen deal pushes tiny companys stock up by double digits at MarketWatch
10:01AM  Biogen enters eye-treatment arena with AGTC deal
09:54AM  Biogen Opens Gene Therapy Partnership Worth About $1 Billion at Bloomberg
07:01AM  AGTC to Host Conference Call and Webcast to Discuss Biogen Collaboration GlobeNewswire
07:00AM  Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology Business Wire
Jul-01-15 07:15AM  Biogen Invests in the Greater Zurich Area: Biopharmaceutical Plant in the Canton of Solothurn Planned PR Newswire
Jun-30-15 06:36PM  U.S. doctors, hospitals reap $6.5 bln from drug and device makers -report Reuters
02:43PM  Why is Celgene So Darn Expensive? at Barrons.com
10:58AM  Why Alexion Stock Could Rip
Jun-29-15 04:35PM  Biogen/Sobi's Hemophilia B Drug Alprolix under EU Review - Analyst Blog
12:55PM  Four ways that Biogen is being a good corporate citizen at bizjournals.com
09:05AM  3 Stocks to Buy if Biotech Crashes at Motley Fool
Jun-26-15 02:00AM  Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX┬« (rFIXFc) Marketing Authorization Application Business Wire
Jun-25-15 07:50AM  Short Sellers Get More Selective on Big Biotech at 24/7 Wall St.
Jun-24-15 05:19PM  Does a Safe Biotechnology Stock Exist? at Investopedia
Jun-23-15 05:02PM  Veteran Investor Sam Isaly Picks Top Biotechs at Barrons.com
03:45PM  Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog
01:16PM  On the move: New hires and job transitions in the local life science industry at bizjournals.com
12:30PM  Biogen Achieves Carbon Neutrality Business Wire
12:10PM  Perrigo Going Up With Or Without Mylan, Says BMO at Investor's Business Daily
Jun-22-15 11:57PM  In middle of MS battle, pioneering foundation closing its doors at bizjournals.com
Jun-20-15 04:00PM  These are the Fortune 500s fastest-growing pharma companies at Fortune
Jun-19-15 03:44PM  Biotech bargain bin
03:19PM  Biotech to break out, buy these names: Analyst at CNBC
02:02PM  Why Biogen Is Inches Away From Changing the World
11:45AM  Report: Big Pharma is getting more worried about drug price pushback at bizjournals.com
Jun-18-15 05:40PM  Biotech's big boost
02:54PM  Biotech ETF Hits Record: How Much Higher Can It Go? at Barrons.com
08:00AM  Biogen and SELF Help Women Reimagine Daily Life with Relapsing Multiple Sclerosis (RMS) PR Newswire
07:30AM  New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use Business Wire
Jun-17-15 04:06PM  The Note Moving Pharma Giants Today
Jun-16-15 07:33PM  3 Reasons That Biogen's Shares Could Rise at Investopedia
08:02AM  Top Health Care Funds: Can Outperformance Continue? at Investor's Business Daily
Jun-15-15 08:23AM  Quartet of GSK cast-off drugs soar to a combined value of $5bn at Financial Times
Jun-12-15 02:20PM  Isis Pharmaceuticals Up on Positive Data on ISIS-SMNRx - Analyst Blog
01:43PM  Why Gilead May be the Strongest Company in the World
09:51AM  Edited Transcript of BIIB shareholder or annual meeting 10-Jun-15 1:00pm GMT
07:57AM  Big Biotech Stocks See Declining Short Interest
Jun-11-15 08:05PM  Biogen's Biosimilars Program Leaps Forward at Investopedia
04:42PM  BIOGEN INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securit
01:36PM  Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference
12:58PM  Isis, Biogen Rare-Disease Drug Aids Infant Survival at Investor's Business Daily
Jun-10-15 11:19AM  Hedge Funds Buying Biotech IPO Operated By Ex-Fund Manager
09:07AM  Comparing Vasco Data Security Internationals Forward PE with QQQ
07:55AM  Short Sellers Lose Some Conviction Against Big Biotech at 24/7 Wall St.
06:00AM  Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress Business Wire
Jun-09-15 08:47AM  Coverage initiated on Biogen by Guggenheim
07:36AM  Roche Takes Another Shot at Alzheimer's After Biogen Success
12:00AM  Roche Takes Another Shot at Alzheimers After Biogen Has Success at Bloomberg
Jun-08-15 03:56PM  Biotech company with RTP roots named No. 1 'green' company by Newsweek at bizjournals.com
Jun-04-15 07:00PM  Cramer: This blue stock is red hot
09:10AM  The Secret to Safely Investing in Biotech at Kiplinger
Jun-03-15 02:40PM  Choate adds former in-house counsel from Boston biotech giant at bizjournals.com
Jun-02-15 02:35PM  Whats so special about specialty drugs? at bizjournals.com
10:40AM  How Does Biogen Make its Money? at Investopedia
May-29-15 03:04PM  How To Avoid Investor Traps And Invest During Turbulent Times at Forbes
11:51AM  This stock is no longer in the Top 20 most held at CNBC
May-28-15 04:01PM  Biogen 2015 Annual Shareholder Meeting Webcast Business Wire
02:59PM  Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in ... Gurufocus
08:25AM  Short Sellers Get Even More Ambitious Against Biotech Leaders at 24/7 Wall St.
May-27-15 07:36PM  PRIMECAP Sells Portions of Its Top Two Stakes
May-26-15 03:30PM  A Sell in May Strategy at Forbes
May-22-15 02:45PM  A Beautiful Biotech Summer? at Barrons.com
May-21-15 02:20PM  BlueBird Bio: Another Biogen Rout In The Making?
01:06PM  Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair at TheStreet
May-20-15 04:01PM  Biogen to Present at Bernsteins 31st Annual Strategic Decisions Conference Business Wire
May-19-15 04:44PM  3 Things Biogen's Management Wants You to Know at Investopedia
03:39PM  Value plays in health care, financials & tech
01:36PM  Good year for stock pickers: Pro
01:06PM  Healthcare Mid-Day Winners and Losers: May 19, 2015
09:39AM  Billionaire Stanley Druckenmillers Top Value Picks Include Illumina, Inc. (ILMN), Biogen Inc (BIIB), LyondellBasell Industries NV (LYB) at Insider Monkey
08:33AM  3 Best Biotech Stocks to Add to Your Portfolio at TheStreet
May-18-15 08:03AM  Is the Stock Market Due for a Correction?
May-15-15 08:37AM  The Morning Download: Hardware Advances Bring Deep Learning, Real-Time Analytics Closer to Enterprise at The Wall Street Journal
May-14-15 06:11PM  Fidelity Adds to Biogen, Amazon and Sells Microsoft, Amex at Bloomberg
04:42PM  Buy Microsoft, Biogen for Performance, Avoid Consumer Discretionary Stocks at TheStreet
12:31PM  Biogen Promotes Former Dell Exec as CIO to 'Drive Innovation' at The Wall Street Journal
May-13-15 04:01PM  Biogen to Present at the 2015 UBS Global Healthcare Conference Business Wire
09:40AM  3 Biotech Stocks See Growing Short Interest
07:30AM  Biogen Names Matt Griffiths as Chief Information Officer Business Wire
May-12-15 08:05AM  Short Sellers Start to Get Nervous on Biotech at 24/7 Wall St.
May-11-15 09:59PM  Is This Biogen's Next Billion-Dollar Blockbuster? at Investopedia
May-08-15 11:41AM  Biogen Announces Massive $5 Billion Stock Repurchase Program: Share Value To Go Up
07:47AM  Early movers: AOL, WHR, PM, CBS, NOK & more at CNBC
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM